Skip to main content
Clinical Trials/NCT02358564
NCT02358564CompletedNot Applicable

Gut Permeability, Sensitivity and Symptomatology: Is There a Link and Explanation for Exacerbation of Symptoms Post Meals

Mayo Clinic4 sites in 1 country39 target enrollmentStarted: February 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
39
Locations
4
Primary Endpoint
Mean Percent of complete epithelial cell loss

Study Overview

Brief Summary

To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of irritable bowel syndrome (IBS).

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Mean Percent of complete epithelial cell loss

Time Frame: 72 hours

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Madhusudan (Madhu) Grover, MBBS

Assistant Professor of Medicine

Mayo Clinic

Study Sites (4)

Loading locations...

Similar Trials

Gut Permeability, Sensitivity and... | Clinical Trial